



Executive Summary:

Overview. Neurodon is a small molecule pharmaceutical company developing first-in-class, disease-modifying small molecules that target endoplasmic reticulum (ER) stress, a key driver in the pathogenesis of many diseases. Neurodon's compounds act by correcting aberrant intracellular calcium handling, a major contributor to ER stress initiation. A large body of evidence has been generated showing that disrupted calcium, and the resultant ER stress, are key pathological drivers in major diseases like Type 1 and Type 2 diabetes, Alzheimer's disease, Parkinson's disease, and various other unmet and rare diseases. We have several compounds that are undergoing late lead optimization and IND-enabling studies. We hope to initiate Phase 1 clinical trials for our diabetes candidate in mid-2024.

Opportunity. By generating the first truly disease-modifying small molecule therapies for unmet diseases, Neurodon is poised to garner a large market share. Type 1 Diabetes is projected to be a \$2.8B market by 2026, with a CAGR of 7.20% (2022-2030). Many therapies are focused on targeting insulin, with mixed success, allowing Neurodon to be an emerging player with a novel mechanism of action (MOA). Our other markets also hold promise: Type 2 diabetes is expected to become a \$57B market by 2029; Parkinson's an \$11.5B market by 2029; Alzheimer's a \$9.6B market by 2027; and DMD a \$14.9B market by 2027 with a 43.70% CAGR.

Advantage. Neurodon is the only company harnessing and restoring calcium with first-in-class modulators. Neurodon's compounds have undergone extensive proof-of-concept studies in animal models of diabetes, obesity, neurodegeneration, and rare diseases. There are no competitors in the market targeting diseases with Neurodon's MOA and industry-leading ER stress platform technology.

Team & Advisors:

Neurodon's team includes experienced professionals who have managed drug development through clinical trials to FDA approval with many years of cumulative experience developing biotechnology products.

- Russell Dahl, Ph.D., CEO and Founder
- Colleen Mauger, R.N., VP of Operations
- Brunde Broady, MBA, Board Member

Neurodon's advisors include world-class experts in their respective fields.

- John Amatruda, M.D., Medical Advisor, Ex-Head of Diabetes at Merck
- Ilya Bezprozvanny, Ph.D., UTSW

- D. James Surmeier, Ph.D., Northwestern University
- Seth Robia, Ph.D., Loyola University Chicago
- Carmella Evans-Molina, M.D., Ph.D., Indiana University
- Steve Davis, Ph.D., J.D., IP, McCarter & English
- Marty Waters, J.D., Corporate Counsel, Wilson Sonsini